abacavir and Fever

Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir

The most serious adverse event caused by abacavir is the hypersensitivity reaction, which is usually associated with the presence of the human leukocyte antigen (HLA) subtype B*5701, as shown in recent studies. We describe the case of a 41-year-old Caucasian female patient, who tested HLA-B*5701 negative and developed fever and severe skin rash 10 weeks after the start of abacavir therapy. Similar reports suggest that not all severe abacavir-induced adverse events occur as a result of classic hypersensitivity reactions, and can present also in HLA-B*5701-negative patients.

Topics: Adult; Dideoxynucleosides; Exanthema; Female; Fever; HIV Infections; HIV-1; HLA-B Antigens; Humans; Reverse Transcriptase Inhibitors

Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Fever; Humans; Middle Aged; Reverse Transcriptase Inhibitors

Topics: Adult; Agranulocytosis; Anemia; Anti-HIV Agents; Dideoxynucleosides; Female; Fever; Humans

The aim of this study was to determine the incidence of abacavir discontinuation within the first two months of treatment and the link with a true hypersensitivity reaction (HSR).. A retrospective study was made between January 1998 and January 2006 on a cohort of HIV positive patients treated by abacavir delivered by the Bordeaux Saint-André University Hospital pharmacy.. Six hundred (and) twenty-eight patients were included. The reasons for non-renewal of abacavir prescription within the first three months of treatment were investigated. Early discontinuation for adverse effects was reported in 32 patients (5.1%): proved diagnosis of HSR (N=10), uncertain diagnosis of HSR (N=8), and no HSR (N=14). The decision for discontinuation was taken by physician after consultation in 76% of cases.

Topics: Dideoxynucleosides; Drug Hypersensitivity; Fever; France; Gastrointestinal Diseases; HIV Infections; Hospitals, University; Humans; Musculoskeletal Diseases; Retrospective Studies

Topics: Adult; Agranulocytosis; Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Fever; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors